Inflammatory Bowel Disease

Infection and Autoimmunity, 2nd edition

Volumn , Issue , 2004, Pages 649-673

  Weinstock, Joel V ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49349100042     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451271-0.50051-X     Document Type: Chapter

References (263)

1. Dalziel TK Chronic interstitial enteritis. Br Med J 1913, 2:1068-1070.
2. Lawen A Uber. Appendictiits fibroplastica. Dtshch Ztschr Chir 1914, 129:221-241.
3. Crohn BB, Ginzburg L, Oppenheimer J Regional ileitis. JAMA 1932, 99:1323-1329.
4. Weinstock JV The granuloma in Crohn's disease. Inflammatory bowel disease 1992, 163-176. Elsevier, Amsterdam. R.P. MacDermott, W.F. Stenson (Eds.).
5. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991, 100(5):t-87. (erratum appears in Gastroenterology 1991 Aug; 101(2):595), Pt 1.
6. Mooney EE, Walker J, Hourihane DO Relation of granulomas to lymphatic vessels in Crohn's disease. J Clin Path 1995, 48(4):335-338.
7. Muneef MA, Memish Z, Mahmoud SA, Sadoon SA, Bannatyne R, Khan Y Tuberculosis in the belly: a review of forty-six cases involving the gastrointestinal tract and peritoneum. (Review, 27 refs). Scand J Gastroenterol 2001, 36(5):528-532.
8. Gan HT, Chen YQ, Ouyang Q, Bu H, Yang XY Differentiation between intestinal tuberculosis and Crohn's disease in endoscopic biopsy specimens by polymerase chain reaction. Am J Gastroenterol 2002, 97(6):1446-1451.
9. Rankin GB Extraintestinal and systemic manifestations of inflammatory bowel disease. (Review, 49 refs). Med Clin North Am 1990, 74(1):39-50.
10. Apgar JT Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. (Review, 115 refs). Semin Dermatol 1991, 10(3):138-147.
11. Balan V, LaRusso NF Hepatobiliary disease in inflammatory bowel disease. (Review 112 refs). Gastroenterol Clin North Am 1995, 24(3):647-669.
12. Gran JT, Husby G Joint manifestations in gastrointestinal diseases. 2. Whipple's disease, enteric infections, intestinal bypass operations, gluten-sensitive enteropathy, pseudomembranous colitis and collagenous colitis. (Review, 190 refs). Dig Dis 1992, 10(5):295-312.
13. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118(2):274-278.
14. Palm O, Moum B, Ongre A, Gran JT Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002, 29(3):511-515.
15. Huang C, Lichtenstein DR Pancreatic and biliary tract disorders in inflammatory bowel disease. (Review, 124 refs). Gastrointest Endosc Clin N Am 2002, 12(3):535-559.
16. Sura ME, Heinrich KA, Suseno M Metronidazole-associated pancreatitis. Ann Pharmacother 2000, 34(10):1152-1155.
17. Markowitz JF Summary of the workshop on 6-mercaptopurine/azathioprine pharmacology. Inflamm Bowel Dis 1998, 4:117-118.
18. Fraquelli M, Losco A, Visentin S, Cesana BM, Pometta R, Colli A, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. (comment). Arch Intern Med 2001, 161(18):2201-2204.
19. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000, 232:43-47.
20. Eaden JA, Abrams KR, Mayberry JF The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48(4):526-535.
21. Bernstein CN, Blanchard JF, Kliewer E, Wajda A Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91(4):854-862.
22. Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, et al. Medical risk factors for small-bowel adenocarcinoma with focus on Crohn disease: a European population-based case-control study. Scand J Gastroenterol 2001, 36(6):641-646.
23. Singer HC, Anderson JG, Frischer H, Kirsner JB Familial aspects of inflammatory bowel disease. Gastroenterology 1971, 61(4):423-430.
24. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sorensen IA, Binder V Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324(2):84-88.
25. Kurata JH, Kantor-Fish S, Frankl H, Godby P, Vadheim CM Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology 1992, 102(6):1940-1948.
26. Niv Y, Abuksis G, Fraser GM Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 2000, 95(3):693-698.
27. Odes HS, Fraser D Ulcerative colitis in Israel: epidemiology, morbidity, and genetics. (Rivew, 56 refs). Public Health Rev 1989, 17(4):297-319.
28. Odes HS, Fraser D, Hollander L Epidemiological data of Crohn's disease in Israel: etiological implications. (Review, 48 refs). Public Health Rev 1989, 17(4):321-335.
29. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988, 29(7):990-996.
30. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. (comment). Nature 2001, 411(6837):603-606.
31. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. (comment). Nature 2001, 411(6837):599-603.
32. Inohara M, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crospo J, et al. Hoat recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003.
33. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003.
34. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. (comment). Gastroenterology 2002, 122(4):867-874.
35. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002, 123(3):679-688.
36. Radlmayr M, Torok HP, Martin K, Folwaczny C The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002, 122(7):2091-2092.
37. Duerr RH The genetics of inflammatory bowel disease. (Review, 110 refs). Gastroenterol Clin N Am 2002, 31(1):63-76.
38. Sashio H, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T, et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics 2002, 53(12):1020-1027.
39. Obana N, Takahashi S, Kinouchi Y, Negoro K, Takagi S, Hiwatashi N, et al. Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand J Gastroenterol 2002, 37(6):699-704.
40. Vermeire S, Peeters M, Vlietinck R, Parkes M, Satsangi J, Jewell D, et al. Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneity. Inflamm Bowel Dis 2000, 6(3):165-170.
41. Aithal GP, Day CP, Leathart J, Daly AK, Hudson M Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immunity 2001, 2(1):44-47.
42. Heresbach D, Alizadeh M, Bretagne JF, Dabadie A, Colombel JF, Pagenault M, et al. TAP gene transporter polymorphism in inflammatory bowel diseases. Scand J Gastroenterol 1997, 32(10):1022-1027.
43. Loftus EV, Sandborn WJ Epidemiology of inflammatory bowel disease. (Review, 173 refs). Gastroenterol Clin North Am 2002, 31(1):1-20.
44. Elliott DE, Urban JF, Argo CK, Weinstock JV Does the failure to acquire helminthic parasites predispose to Crohn's disease?. FASEB J 2000, 14(12):1848-1855.
45. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 149(10):916-924.
46. Loftus EV, Schoenfeld P, Sandborn WJ The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. (Review, 25 refs). Aliment Pharmacol Ther 2002, 16(1):51-60.
47. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996, 39(5):690-697.
48. Sonnenberg A, Wasserman IH Epidemiology of inflammatory bowel disease among U.S. military veterans. Gastroenterology 1991, 101(1):122-130.
49. Delco F, Sonnenberg A Military history of patients with inflammatory bowel disease: an epidemiological study among U.S. veterans (comment). Am J Gastroenterol 1998, 93(9):1457-1462.
50. Rolon PA Gastrointestinal pathology in South America. Israel J Med Sci 1979, 14(4):318-321.
51. Hutt MS Epidemiology of chronic intestinal disease in middle. Africa. Israel J Med Sci 1979, 15(4):314-317.
52. Segal I Ulcerative colitis in a developing country of Africa: the Baragwanath experience of the first 46 patients. Int J Colorectal Dis 1988, 3(4):222-225.
53. Yang SK, Loftus EV, Sandborn WJ Epidemiology of inflammatory bowel disease in Asia. (Review, 102 refs). Inflamm Bowel Dis 2001, 7(3):260-270.
54. Wright JP, Marks IN, Jameson C, Garisch JA, Burns DG, Kottler RE Inflammatory bowel disease in Cape Town, 1975-1980. Part II. Crohn's disease. S Afr Med J 1983, 63(7):226-229.
55. Carr I, Mayberry JF The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second-generation South Asians in Leicester (1991-1994). Am J Gastroenterol 1999, 94(10):2918-2922.
56. Jayanthi V, Probert CS, Pinder D, Wicks AC, Mayberry JF Epidemiology of Crohn's disease in Indian migrants and the indigenous population in Leicestershire. Q J Med 1992, 82(298):125-138.
57. Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut 1993, 34(1):1547-1551.
58. Ekbom A, Helmick C, Zack M, Adami HO The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991, 100(2):350-358.
59. Sonnenberg A Occupational distribution of inflammatory bowel disease among German employees. Gut 1990, 31(9):1037-1040.
60. Laharie D, Debeugny S, Peeters M, Van Gossum A, Gower-Rousseau C, Belaiche J, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001, 120(4):816-819.
61. Duggan AE, Usmani I, Neal KR, Logan RF Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. (see comments). Gut 1998, 43(4):494-498.
62. Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D Inflammatory bowel disease and domestic hygiene in infancy. (comment). Lancet 1994, 343(8900):766-767.
63. Novis BH, Marks IN, Bank S, Louw JH Incidence of Crohn's disease at Groote Schuur Hospital during 1970-1974. S Afr Med J 1975, 49(17):693-697.
64. Odes HS, Fraser D, Krawiec J Inflammatory bowel disease in migrant and native Jewish populations of southern Israel. Scand J Gastroenterol Suppl 1989, 170:36-38.
65. Grossman A, Fireman Z, Lilos P, Novis B, Rozen P, Gilat T Epidemiology of ulcerative colitis in the Jewish population of central Israel 1970-1980. HepatoGastroenterology 1989, 36(4):193-197.
66. Firenan Z, Grossman A, Lilos P, Eshchar Y, Theodor E, Gilat T Epidemiology of Crohn's disease in the Jewish population of central Israel, 1970-1980. Am J Gastroenterol 1989, 84(3):255-258.
67. Odes HS, Fraser D, Krugliak P, Fenyves D, Fraser GM, Sperber AD Inflammatory bowel disease in the Bedouin Arabs of southern Israel: rarity of diagnosis and clinical features. Gut 1991, 32(9):1024-1026.
68. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. (comment). Lancet 1991, 338(8770):771-774.
69. Sartor RB Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. (Review, 30 refs). Aliment Pharmacol Ther 1997, 11(Suppl-22).
70. Salas SD, Heifetz R, Barrett-Connor E Intestinal parasites in Central American immigrants in the United States. Arch Intern Med 1990, 150(7):1514-1516.
71. Healy GR, Gleason NN, Bokat R, Pond H, Roper M Prevalence of ascariasis and amebiasis in Cherokee Indian school children. Public Health Rep 1969, 84(10):907-914.
72. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996, 173(1):269-272.
73. Bentwich Z, Weisman Z, Moroz C, Bar-Yehuda S, Kalinkovich A Immune dysregulation in Ethiopian immigrants in Israel: relevance to helminth infections?. Clin Exp Immunol 1996, 103(2):239-243.
74. Borkow G, Leng Q, Weisman Z, Stein M, Galai N, Kalinkovich A, et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 2000, 106(8):1053-1060.
75. Weinstock JV, Summers RW, Elliott DE, Qadir K, Urban JF, Thompson R The possible link between de-worming and the emergence of immunological disease. (Review, 22 refs). J Lab Clin Med 2002, 139(6):334-338.
76. Sewell DL, Reinke EK, Hogan LH, Sandor M, Fabry Z Immunoregulation of CNS autoimmunity by helminth and mycobacterial infections. (Review, 79 refs). Immunol Letters 2002, 82(1-2):101-110.
77. Yazdanbakhsh M, van den BA, Maizels RM Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. (comment). (Review, 50 refs). Trends Immunol 2001, 22(7):372-377.
78. Yazdanbakhsh M, Kremsner PG, van Ree R Allergy, parasites, and the hygiene hypothesis. (Review, 67 refs). Science 2002, 296(5567):490-494.
79. Greenfield C, Aguilar R, Pounder RE, Williams T, Danvers M, Marper SR, et al. Clostridium difficile and inflammatory bowel disease. Gut 1983, 24(8):713-717.
80. Rolny P, Jarnerot G, Mollby R Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol 1983, 18(1):61-64.
81. Cottone M, Pietrosi G, Martorana G, Casa A, Pecoraro G, Oliva L, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis (comment). Am J Gastroenterol 2001, 96(3):773-775.
82. Bloomfeld RS Are we missing CMV infections in patients hospitalized with severe colitis?. Inflamm Bowel Dis 2001, 7(4):348-349.
83. Sebastian-Planas M, Barrio-Merino A, Avilla-Hernandez J, Fortes-Alen JD, Villar Rubin S, Casas-Rivero J, et al. Cutomegalovirus infection of the colon in ulcerative colitis: a pediatric case. J Pediatr Gastroenterol Nutr 1996, 23(2):186-190.
84. Robertson DJ, Sandler RS Measles virus and Crohn's disease: a critical appraisal of the current literature. (Review, 35 refs). Inflamm Bowel Dis 2001, 7(1):51-57.
85. Van Kruiningen HJ Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. (Review, 92 refs). Inflamm Bowel Dis 1999, 5(3):183-191.
86. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. (comment). N Engl J Med 2001, 345(15):1098-1104.
87. Ryan P, Bennett MW, Aarons S, Lee G, Collins JK, O'Sullivan GC, et al. PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut 2002, 51(5):665-670.
88. Calkins BM A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989, 34(12):1841-1854.
89. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999, 13(11):1403-1411.
90. Cottone M, Rosselli M, Orlando A, Oliva L, Puleo A, Cappello M, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994, 106(3):643-648.
91. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001, 120(5):1093-1099.
92. Andersson RE, Olaison G, Tysk C, Ekbom A Appendectomy and protection against ulcerative colitis. N Eng J Med 2001, 344(11):808-814.
93. Derby LE, Jick H Appendectomy protects against ulcerative colitis. Epidemiology 1998, 9(2):205-207.
94. Russel MG, Dorant E, Brummer RJ, van de Kruijs MA, Muris JW, Bergers JM, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. (see comments). Gastroenterology 1997, 113(2):377-382.
95. Andersson RE, Olaison G, Tysk C, Ekbom A Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 2003, 124(1):40-46.
96. Donowitz M Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway. Gastroenterology 1985, 88(2):580-587.
97. Gibson GR, Whitacre EB, Ricotti CA Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. (Review, 44 refs). Arch Int Med 1992, 152(3):625-632.
98. Banerjee AK, Peters TJ Crohn's disease and NSAID enteropathy-a, unifying model. (comment). Gastroenterology 1990, 99(4):1190-1192.
99. Berg DJ, Zhang J, Weinstock JV, Ismail H, Moore S, Lynch RG Rapid development of colttis in NSAID-treated IL-10 deficient mice. Gastroenterology 2002.
100. Lavy A, Militianu D, Eidelman S Diseases of the intestine mimicking Crohn's disease. J Clin Gastronterol 1992, 15(1):17-23.
101. Godet PG, May GR, Sutherland LR Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995, 37(5):668-673.
102. Moum B, Aadland E, Ekbom A, Vatn MH Seasonal variations in the onset of ulcerative colitis. Gut 1996, 38(3):376-378.
103. Zeng L, Anderson FH Seasonal change in the exacerbations of Crohn's disease. Scand J Gastroenterol 1996, 31(1):79-82.
104. Strober W, Fuss IJ, Blumberg RS The immunology of mucosal models of inflammation. (Review, 212 refs). Ann Rev Immunol 2002, 20:495-549.
105. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996, 98(4):1010-1020.
106. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. (comment). J Clin Invest 2001, 107(6):695-702.
107. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL Phenotypically distinct subsets of CD4+T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993, 5(11):1461-1471.
108. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. (see comments). Cell 1993, 75(2):274-282.
109. Maloy KJ, Powrie F Regulatory T cells in the control of immune pathology. (Review, 112 refs). Nature Immunol 2001, 2(9):816-822.
110. Gorelik L, Flavell RA Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000, 12(2):171-181.
111. Read S, Malmstrom V, Powrie F Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the tunction of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192(2):295-302.
112. Leach MW, Davidson NJ, Fort MM, Powrie F, Rennick DM The role of IL-10 in inflammatory bowel disease: "of mice and men". (Review, 137 refs). Toxicol Pathol 1999, 27(1):123-133.
113. Fowler S, Powrie F Control of immune pathology by IL-10-secreting regulatory T cells. (Review, 50 refs). Springer Semin Immunopathol 1999, 21(3):287-294.
114. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+T cells. J Exp Med 1996, 183(6):2669-2674.
115. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. (see comments). Cell 1993, 75(2):253-261.
116. Ludviksson BR, Gray B, Strober W, Ehrhardt RO Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J Immunol 1997, 158(1):104-111.
117. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268(5216):1472-1476.
118. Poussier P, Ning T, Chen J, Banerjee D, Julius M Intestinal inflammation observed in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. (comment). Gastroenterology 2000, 118(5):880-891.
119. Hollander GA, Simpson SJ, Mizoguchi E, Nichogiannopoulou A, She J, Gutierrez-Ramos JC, et al. Severe colitis in mice with aberrant thymic selection. Immunity 1995, 3(1):27-38.
120. Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A Spontaneous chronic colitis in TCR alpha-mutant mice; an experimental model of human ulcerative colitis. (Review, 66 refs). Int Rev Immunol 2000, 19(1):123-138.
121. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17(5):629-638.
122. Wirtz S, Finotto S, Kanzler S, Lohse AW, Blessing M, Lehr HA, et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+T cells that respond to bacterial antigens. J Immunol 1999, 162(4):1884-1888.
123. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002, 195(9):1129-1143. (erratum appears in J Exp Med 2002 Jun 3; 195(11):1513).
124. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002, 196(12):1563-1574.
125. Davidson NJ, Fort MM, Muller W, Leach MW, Rennick DM Chronic colitis in IL-10-/-mice: insufficient counter regulation of a Th1 response. (Review, 128 refs). Int Rev Immunol 2000, 19(1):91-121.
126. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998, 66(11):5224-5231.
127. Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998, 187(4):571-578.
128. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001, 193(4):471-481.
129. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1 d upregulation. Immunity 2002, 16(2):219-230.
130. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997, 186(10):1749-1756.
131. Kinoshita N, Hiroi T, Ohta N, Fukuyama S, Park EJ, Kiyono H Autocrine IL-15 mediates intestinal epithelial cell death via the activation of neighboring intraepithelial NK cells. J Immunol 2002, 169(11):6187-6192.
132. Mennechet FJ, Kasper LH, Rachinel N, Li W, Vandewalle A, Buzoni-Gatel D Lamina propria CD4+ T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen. J Immunol 2002, 168(6):2988-2996.
133. Hermiston ML, Gordon JI Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995, 270(5239):1203-1207.
134. Panwala CM, Jones JC, Viney JL A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998, 161(10):5733-5744.
135. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002, 109(7):883-893.
136. Andoh A, Kinoshita K, Rosenberg I, Podolsky DK Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol 2001, 167(7):3887-3893.
137. Schultz M, Tonkonogy SL, Sellon RK, Veltkamp C, Godfrey VL, Kwon J, et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999, 276(6:Pt1):t-72.
138. Veltkamp C, Tonkonogy SL, De Jong YP, Albright C, Grenther WB, Balish E, et al. Continous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon 26) mice. Gastroenterology 2001, 120(4):900-913.
139. Sartor RB The influence of normal microbial flora on the development of chronic mucosal inflammation. (Review, 72 refs). Res Immunol 1997, 148(8-9):567-576.
140. Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998, 187(6):855-864.
141. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001, 69(4):2277-2285.
142. Cong Y, Weaver CT, Lazenby A, Elson CO Bacterialreactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol 2002, 169(11):6112-6119.
143. Elson CO, Cong Y, Sundberg J The C3H/HeJBir mouse model: a high susceptibility phenotype for colitis. (Review, 14 refs). Int Rev Immunol 2000, 19(1):63-75.
144. Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 1998, 93(2):189-201.
145. Cornet A, Savidge TC, Cabarrocas J, Deng WL, Colombel JF, Lassmann H, et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease?. Proc Natl Acad Sci USA 2001, 98:13306-13311.
146. Dombrowicz D, Nutten S, Desreumaux P, Neut C, Torpier G, Peeters M, et al. Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. J Exp Med 2001, 193(1):25-34.
147. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997, 158(5):2099-2106.
148. Krieglstein CF, Cerwinka WH, Sprague AG, Laroux FS, Grisham MB, Koteliansky VE, et al. Collagen-binding integrin alpha 1 beta 1 regulates intestinal inflammation in experimental colitis. J Clin INvest 2002, 110(12):1773-1782.
149. Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF, et al. Exposure to schistosome eggs protects mice from TNBS colitis. Am J Physiol 2003, 284:G385-G391.
150. Sewell D, Qing Z, Reinke E, Elliott E, Weinstock JV, Sandor M, et al. Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Intl Immunol 2003, 15:59-69.
151. Dunne C Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. (Review, 172 refs). Inflamm Bowel Dis 2001, 7(2):136-145.
152. Scott MG, Nahm MH, Macke K, Nash GS, Bertovich MJ, MacDermott RP Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol 1986, 66(1):209-215.
153. Broberger O, Perlamann P Autoantibodies in human ulcerative colitis. J Exp Med 1959, 110:657.
154. Dasgupta A, Mandal A, Das KM Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody. Gut 1994, 35(12):1712-1717.
155. Geng X, Biancone L, Dai HH, Lin JJ, Yoshizaki N, Dasgupta A, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998, 114(5):912-922.
156. Taniguchi M, Geng X, Glazier KD, Dasgupta A, Lin JJ, Das KM Cellular immune response against tropo myosin isoform 5 in ulcerative colitis. Clin Immunol 2001, 101(3):289-295.
157. Lee JC, Cevallos AM, Naeem A, Lennard-Jones JE, Farthing MJ Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells. Gut 1999, 44(2):196-202.
158. Inoue N, Watanabe M, Sato T, Okazawa A, Yamazaki M, Kanai T, et al. Restricted V(H) gene usage in lamina propria B cells producing anticolon antibody from patients with ulcerative colitis. Gastroenterology 2001, 121(1):15-23.
159. Folwaczny C, Noehl N, Tschop K, Endres SP, Heldwein W, Loeschke K, et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997, 113(1):101-106.
160. Seibold F, Mork H, Tanza S, Muller A, Holzhuter C, Weber P, et al. Pancreatic autoantibodies in Crohn's disease: a family study. (comment). Gut 1997, 40(4):481-484.
161. Folwaczny C, Noehl N, Endres SP, Heldwein W, Loeschke K, Fricke H Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig Dis Sci 1997, 42(8):1593-1597.
162. Folwaczny C, Loeschke K, Schnettler D, Jager G, Wiebecke B, Hoelscher M, et al. Endothelial cell auto-antibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. Clin Immunol 2000, 95(3):197-202.
163. Ryan FP, Ward AM, Holdsworth CD Autoimmunity, inflammatory bowel disease and hyposplenism. Q J Med 1991, 78(285):59-63.
164. Nielsen H, Wiik A, Elmgreen J Granulocyte specific antinuclear antibodies in ulcerative colitis. Aid in differential diagnosis of inflammatory bowel disease. Acta Pathologica, Microbiologica, et Immunologica Scandinavica-Section C, Immunology 1983, 91(1):23-26.
165. Seibold F, Slametschka D, Gregor M, Weber P Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. (comment). Gastroenterology 1994, 107(2):532-536.
166. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001, 96(3):730-734.
167. Papo M, Quer JC, Pastor RM, Garcia-Pardo G, Prats E, Mirapeix E, et al. Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease. Am J Gastroenterol 1996, 91(8):1512-1515.
168. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. (comment). Gut 2000, 46(1):58-63.
169. Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001, 36(2):196-201.
170. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988, 297(6656):1105-1106.
171. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002, 122(5):1242-1247.
172. Holtmeier W, Hennemann A, May E, Duchmann R, Caspary WT T cell receptor delta repertoire in inflamed and noninflamed colon of patients with IBD analyzed by CDR3 spectratyping. Am J Physiol Gastrointest Liver Physiol 2002, 282(6):G1024-G1034.
173. Liu Z, Colpaert S, D'Haens GR, Kasran A, de Boer M, Rutgeerts P, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999, 163(7):4049-4057.
174. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich MJ, Nash GS Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. (see comments). Gastroenterology 1991, 101(4):1020-1030.
175. Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, et al. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol 2002, 14(3):237-241.
176. Shalon L, Gulwani-Akolkar B, Fisher SE, Akolkar PN, Panja A, Mayer L, et al. Evidence for an altered T-cell receptor repertoire in Crohn's disease. Autoimmunity 1994, 17(4):301-307.
177. May E, Lambert C, Holtmeier W, Hennemann A, Zeitz M, Duchmann R Regional variation of the alphabeta T cell repertoire in the colon of healthy individuals and patients with Crohn's disease. Human Immunol 2002, 63(6):467-480.
178. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. (comment). Gut 1999, 44(6):812-818.
179. Nakajima A, Kodama T, Yazaki Y, Takazoe M, Saito N, Suzuki R, et al. Specific clonal T cell accumulation in intestinal lesions of Crohn's disease. J Immunol 1996, 157(12):5683-5688.
180. MacDermott RP, Bragdon MJ, Jenkins KM, Franklin GO, Shedlofsky S, Kodner IJ Human intestinal mononuclear cells. II. Demonstration of a naturally occurring subclass of T cells which respond in the allogeneic mixed leukocyte reaction but do not effect cell-mediated lympholysis. Gastroenterology 1981, 80(4):748-757.
181. MacDermott RP, Franklin GO, Jenkins KM, Kodner IJ, Nash GS, Weinrieb IJ Human intestinal mononuclear cells. I. Investigation of antibody-dependent, lectin-induced, and spontaneous cell-mediated cytotoxic capabilities. Gastroenterology 1980, 78(1):47-56.
182. MacDermott RP, Nash GS, Bertovich MJ, Seiden MV, Bragdon MJ, Beale MG Alterations of IgM, IgG, and IgA Synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology 1981, 81(5):844-852.
183. Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999, 116(3):557-565.
184. Boirivant M, Pica R, DeMaria R, Testi R, Pallone F, Strober W Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest 1996, 98(11):2616-2622.
185. Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W Regulation of T-cell apoptosis in inflammatory bowel disease: to die or notto die, that is the mucosal question. Trends Immunol 2001, 22(1):21-26. (erratum appears in Trends Immunol 2001 Apr; 22(4):225) (Review, 38 refs).
186. Suzuki A, Sugimura K, Ohtsuka K, Hasegawa K, Suzuki K, Ishizuka K, et al. Fas/Fas ligand expression and characteristics of primed CD45RO+ T cells in the inflamed mucosa of ulcerative colitis. Scand J Gastroenterol 2000, 35(12):1278-1283.
187. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999, 163(2):1081-1090.
188. Levine AD, Fiocchi C Regulation of life and death in lamina propria T cells. (Review, 54 refs). Sem Immunol 2001, 13(3):195-199.
189. Jeziorska M, Haboubi N, Schofield P, Woolley DE Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique. J Pathol 2001, 194(4):484-492.
190. D'Arienzo A, Manguso F, Astarita C, D'Armiento FP, Scarpa R, Gargano D, et al. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol 2000, 35(6):624-631.
191. Parrello T, Monteleone G, Cucchiara S, Monteleone I, Sebkova L, Doldo P, et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 2000, 165(12):7234-7239.
192. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la MC, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerattve colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157(3):1261-1270.
193. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993, 78(1):127-131.
194. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997, 150(3):823-832.
195. Autschbach F, Schurmann G, Qiao L, Merz H, Wallich R, Meuer SC Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchows Archiv 1995, 426(1):51-60.
196. Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348(7):601-608.
197. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996, 39(5):684-689.
198. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002, 168(10):5342-5351.
199. Holtmann MH, Douni E, Schutz M, Zeller G, Mudter J, Lehr HA, et al. Tumor necrosis factor-receptor 2 is upregulated on lamina propria t cells in Crohn's disease and promotes experimental colitis in vivo. Eur J Immunol 2002, 32(11):3142-3151.
200. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997, 159(12):6276-6282.
201. McAlindon ME, Hawkey CJ, Mahida YR Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatorybowel disease. Gut 1998, 42(2):214-219.
202. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature Med 2000, 6(5):583-588.
203. Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF, Foley E, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999, 162(11):6829-6835.
204. Kanai T, Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, et al. Macrophage-derived Il-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001, 121(4):875-888.
205. Corbaz A, ten Hove T, Herren S, Graber P, Schwartsburd B, Belzer I, et al. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J Immunol 2002, 168(7):3608-3616.
206. Liu Z, Geboes K, Colpaert S, D'Haens GR, Rutgeerts P, Ceuppens JL IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 2000, 164(7):3608-3615.
207. Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, et al. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease. (comment). Gut 2001, 49(6):795-803.
208. Colpaert S, Vanstraelen K, Liu Z, Penninckx F, Geboes K, Rutgeerts P, et al. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin Immunol 2002, 102(1):68-76.
209. di Mola FF, Friess H, Scheuren A, Di Sebastiano P, Graber H, Egger B, et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999, 229(1):67-75.
210. Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut 2002, 51(6):818-826.
211. MacDermott RP, Sanderson IR, Reinecker HC The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. (Review, 136 refs). Inflamm Bowel Dis 1998, 4(1):54-67.
212. MacDermott RP Chemokines in the inflammatory bowel diseases (Review, 47 refs). J Clin Immunol 1999, 19(5):266-272.
213. Reinecker HC, Loh EY, Ringler DJ, Mehta A, Rombeau JL, MacDermott RP Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995, 108(1):40-50.
214. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000, 164(6):3368-3376.
215. Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, Deem R, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001, 121(2):246-254.
216. Binion DG, West GA, Volk EE, Drazba JA, Ziats NP, Petras RE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998, 352(9142):1742-1746.
217. Oshitani N, Hato F, Kitagawa S, Masuyama J, Higuchi K, Matsumoto T, et al. Expression of 4C8 antigen, a novel transendothelial migration-associated molecule on activated T lymphocytes, in inflammatory bowel disease. J Pathol 2002, 197(5):589-594.
218. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. (comment). N Engl J Med 2003, 348(1):24-32.
219. Nielsen OH, Rask-Madsen J Mediators of inflammation in chronic inflammatory bowel disease. (Review, 63 refs). Scand J Gastroenterol Supp 1996, 216:149-159.
220. Schroeder KW Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. (Review, 68 refs). Scand J Gastroenterol Supp 2002, 236:42-47.
221. Campieri M New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. (Review, 42 refs). Gut 2002, 50(Suppl-6).
222. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. (see comments). Gut 1997, 40(5):619-622.
223. Shanahan F Brain-gut axis and mucosal immunity: a perspective on mucosal psychoneuroimmunology. (Review, 43 refs). Sem Gastrointest Dis 1999, 10(1):8-13.
224. Goode T, O'Connell J, Sternini C, Anton P, Wong H, O'Sullivan GC, et al. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localization. J Immunol 1998, 161(5):2232-2240.
225. Goode T, O'Connell J, Ho WZ, O'Sullivan GC, Collins JK, Douglas SD, et al. Differential expression of neurokinin-1 receptor by human mucosal and peripheral lymphoid cells. Clin Diag Lab Immunol 2000, 7(3):371-376.
226. Sandor M, Weinstock JV, Wynn TA Granulomas in schistosome and mycobacterial infections: a model of local immune responses. Trends Immunol 2003, 24(1):44-52.
227. Di Sebastiano P, Grossi L, di Mola FF, Angelucci D, Friess H, Marzio L, et al. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci 1999, 44(2):439-444.
228. Roberts PJ, Riley GP, Morgan K, Miller R, Hunter JO, Middleton SJ The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon. J Clin Pathol 2001, 54(4):293-297.
229. McKenzie SJ, Baker MS, Buffinton GD, Doe WF Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996, 98(1):136-141.
230. Franchimont D, Louis E, Simon S, Belaiche J Intestinal permeability in Crohn's disease. (Review, 35 refs). Acta Gastroenterol Belg 1996, 59(1):15-19.
231. Gitter AH, Wullstein F, Fromm M, Schulzke JD Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001, 121(6):1320-1328.
232. Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, et al. Functional expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa. (see comments). Gastroenterology 1999, 117(3):536-545.
233. Campbell N, Yio XY, So LP, Li Y, Mayer L The intestinal epithelial cell: processing and presentation of antigen to the mucosal immune system. (Review, 63 refs). Immunol Rev 1999, 172:315-324.
234. Allez M, Brimnes J, Dotan I, Mayer L Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 2002, 123(5):1516-1526.
235. Blumberg RS Current concepts in mucosal immunity. II. One size fits all: nonclassical MHC molecules fulfill multiple roles in epithelial cell function. (Review, 40 refs). Am J Physiol 1998, 274(2:Pt 1):t-31.
236. Graham MF, Willey A, Adams J, Yager D, Diegelmann RF Interleukin 1 beta down-regulates collagen and augments collagenase expression in human intestinal smooth muscle cells. Gastroenterology 1996, 110(2):344-350.
237. McKaig BC, Hughes K, Tighe PJ, Mahida YR Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002, 282(1):C172-C182.
238. Pucilowska JB, Williams KL, Lund PK, Fibrogenesis IV Fibrosis and inflammatory bowel disease: cellular mediators and animal models. (Review, 29 refs). Am J Physiol Gastrointest Liver Physiol 2000, 279(4):G653-G659.
239. Stein RB, Lichtenstein GR Medical therapy for Crohn's disease: the state of the art. (Review, 164 refs). Surg Clin N Am 2001, 81(1):71-101.
240. Sutherland LR Mesalamine for the prevention of post-operative recurrence: is nearly there the same as being there? (letter; comment) (see comments). (Review, 17 refs). Gastroenterology 2000, 118(2):436-438.
241. Lewis JD, Schwartz JS, Lichtenstein GR Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118(6):1018-1024.
242. Rutgeerts PJ Review article: the limitations of corticosteroid therapy in Crohn's disease. (Review, 74 refs). Aliment Pharmacol Ther 2001, 15(10):1515-1525.
243. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG The effectiveness of budesonide therapy for Crohn's disease. (Review, 36 refs). Alim Pharmacol Thera 2002, 16(8):1509-1517.
244. Sutherland LR Maintenance therapy for inflammatory bowel disease: what really works. (Review, 40 refs). Can J Gastroenterol 1997, 11(3):261-264.
245. Sands BE Medical therapy of steroid-resistant Crohn's disease. (Review, 21 refs). Can J Gastroenterol 2000, 14(Suppl-37C).
246. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. (see comments). N Eng J Med 2000, 342(22):1627-1632.
247. Tremaine WJ Inflammatory bowel disease workshop. Inflamm Bowel Dis 1998, 4:292-295. Maintenance therapy in IBD. (Review, 34 refs), (4).
248. Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Eng J Med 1997, 337(15):1029-1035.
249. Targan SR Biology of inflammation in Crohn's disease: mechanisms of action of anti-TNF-a therapy. (Review, 27 refs). Can J Gastroenterol 2000, 14(Suppl-16C).
250. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
251. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991, 32(9):1071-1075.
252. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. (see comments). Gastroenterology 1995, 108(6):1617-1621.
253. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999, 94(3):674-678.
254. Colombel JF, Cortot A, Van Kruiningen HJ Antibiotics in Crohn's disease. (comment). (Review, 10 refs). Gut 2001, 48(5):647.
255. Forbes A Review article: Crohn's disease-the role of nutritional therapy. (Review, 31 refs). Aliment Pharmacol Ther 2002, 16(Suppl-52).
256. Ruemmele FM, Roy CC, Levy E, Seidman EG Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? (Review, 50 refs). J Ped 2000, 136(3):285-291.
257. Fazio VW, Wu JS Surgical therapy for Crohn's disease of the colon and rectum. (Review, 89 refs). Surg Clin N Am 1997, 77(1):197-210.
258. Becker JM Surgical therapy for ulcerative colitis and Crohn's disease. (Review, 42 refs). Gastroenterol Clin N Am 1999, 28(2):371-390.
259. Stocchi L, Pemberton JH Pouch and pouchitis. (Review, 65 refs). Gastroenterol Clin N Am 2001, 30(1):223-241.
260. Michetti P, Peppercorn MA Medical therapy of specific clinical presentations. (Review, 146 refs). Gastroenterol Clin N Am 1999, 28(2):353-370.
261. Jani N, Regueiro MD Medical therapy for ulcerative colitis. (Review, 156 refs). Gastroenterol Clin N Am 2002, 31(1):147-166.
262. Steinhart H Maintenance therapy in Crohn's disease. (Review, 49 refs). Can J Gastroenterol 2000, 14(Suppl-28C).
263. Beattie RM Therapy of Crohn's disease in childhood. (Review, 87 refs). Paediatric Drugs 2000, 2(3):193-203.